Terumo Corp
TSE:4543
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2 074.3076
2 987.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Terumo Corp stock under the Base Case scenario is 2 424.68 JPY. Compared to the current market price of 2 921.5 JPY, Terumo Corp is Overvalued by 17%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Terumo Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Terumo Corp cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Terumo Corporation, founded in 1921 and headquartered in Tokyo, Japan, has carved a significant niche in the global healthcare landscape as a leader in medical technology. With a steadfast commitment to enhancing the quality of life, Terumo focuses on innovative solutions in areas such as blood management, cardiovascular interventions, and surgical devices. Through a history of groundbreaking research and development, Terumo has established a robust portfolio of products that not only meet immediate clinical needs but also pave the way for advancements in patient care. The company’s dedication to sustainability and social responsibility further solidifies its reputation as a trustworthy and...
Terumo Corporation, founded in 1921 and headquartered in Tokyo, Japan, has carved a significant niche in the global healthcare landscape as a leader in medical technology. With a steadfast commitment to enhancing the quality of life, Terumo focuses on innovative solutions in areas such as blood management, cardiovascular interventions, and surgical devices. Through a history of groundbreaking research and development, Terumo has established a robust portfolio of products that not only meet immediate clinical needs but also pave the way for advancements in patient care. The company’s dedication to sustainability and social responsibility further solidifies its reputation as a trustworthy and forward-thinking organization committed to making a positive impact on society.
For investors, Terumo presents an attractive opportunity characterized by steady growth, a diverse global presence, and a solid financial foundation. The company's strategic focus on expanding its international footprint, particularly in emerging markets, positions it to capitalize on the rising demand for healthcare innovations. With an increasingly aging population and a growing emphasis on preventative care and advanced treatments, Terumo's comprehensive array of products is well-placed to address these market dynamics. As it continues to invest in R&D and forge strategic partnerships, Terumo Corporation not only stands as a resilient player in the medical technology sector but also as a company poised for long-term growth and value creation for its shareholders.
Terumo Corporation is a global medical technology company based in Japan that focuses on manufacturing and distributing a wide range of medical devices and equipment. The company operates in several core business segments:
-
Cardiovascular: Terumo develops products for cardiovascular surgery and interventional procedures. This includes devices such as heart-lung machines, vascular grafts, and catheter-based systems for diagnosing and treating cardiovascular diseases.
-
Blood Management: This segment includes the development and production of products related to blood collection, storage, and transfusion. Terumo provides blood bags, platelet preparation systems, and other devices that facilitate safe and efficient blood management in hospitals and blood banks.
-
Diabetes Care: Terumo offers various devices and supplies for diabetes management, including insulin delivery systems such as insulin pens and continuous glucose monitoring systems.
-
Surgical: This segment encompasses a range of products and technologies used in various surgical procedures. These include sutures, needles, and other surgical instruments that are essential for effective surgical practices across different specialties.
-
General Hospital: Terumo provides a variety of medical devices used in general healthcare settings, such as intravenous (IV) therapy equipment, and related consumables that support patient care.
-
Others: Terumo also explores other opportunities in the healthcare sector, including regenerative medicine and advanced therapeutic areas. This segment may involve research and development of new technologies and solutions aimed at improving patient outcomes.
Through these core business segments, Terumo aims to enhance the quality of life for patients and support healthcare professionals with innovative medical solutions.
Terumo Corporation, a leading global manufacturer of medical devices and equipment, possesses several competitive advantages that distinguish it from its rivals:
-
Innovation and R&D Investment: Terumo places a strong emphasis on research and development. Its commitment to innovation leads to the development of cutting-edge medical devices, which can offer better performance and efficacy compared to competitors.
-
Wide Product Range: Terumo has a diverse portfolio that spans various medical fields, including cardiovascular therapies, blood and cell technologies, and pharmaceutical products. This diversification helps it capture different segments of the market and reduces dependence on any single product line.
-
Quality and Reliability: Terumo is known for its high-quality manufacturing standards. Its reputation for reliability can lead to stronger customer loyalty, benefiting from repeat business in the healthcare sector where safety and effectiveness are paramount.
-
Global Reach with Local Adaptation: Terumo has an extensive global presence, with production and sales operations in multiple countries. This allows the company to adapt its products to local markets while leveraging economies of scale in operations.
-
Strategic Partnerships and Collaborations: Terumo often engages in partnerships with healthcare organizations, research institutions, and other companies, enabling it to access new markets, technologies, and insights that can inform product development and enhance its competitive position.
-
Strong Brand Recognition: With a long history and a strong reputation in the medical device industry, Terumo benefits from brand recognition that can influence purchasing decisions in its favor.
-
Focus on Sustainability and Ethics: As healthcare systems move towards more sustainable practices, Terumo's commitment to environmental and social responsibility can provide a competitive advantage in tendering processes and customer relationships.
-
Customer-Centric Approach: Terumo emphasizes understanding the needs of healthcare professionals and patients, allowing it to tailor products and services that meet the evolving demands of the healthcare community better than its competitors.
By leveraging these competitive advantages, Terumo Corporation can maintain and possibly extend its market leadership in the medical technology field.
Terumo Corporation, a prominent player in the medical devices and healthcare market, faces several risks and challenges in the near future:
-
Regulatory Changes:
- Medical devices are subject to stringent regulations. Changes in regulations or approval processes in major markets (like the US, EU, and Japan) can impact product timelines and compliance costs.
-
Market Competition:
- The medical device industry is highly competitive. New entrants and advancements from existing competitors can pressure Terumo to innovate continuously while maintaining pricing strategies.
-
Technological Advancements:
- Rapid technological changes require Terumo to invest significantly in R&D to keep up with new developments. Failing to innovate could lead to a loss of market share.
-
Supply Chain Disruptions:
- Global supply chain issues, exacerbated by events like pandemics or geopolitical tensions, can affect production timelines and costs for raw materials and components.
-
Economic Uncertainty:
- Economic fluctuations can impact healthcare spending. Budget constraints in healthcare systems can lead to reduced sales, particularly in developed markets.
-
Intellectual Property Risks:
- The medical device industry often faces patent challenges and intellectual property disputes. Issues regarding patents can lead to costly litigation or the inability to market certain products.
-
Reimbursement Challenges:
- Changes in healthcare reimbursement policies can affect the marketability of Terumo's products and impact profit margins. Ensuring that products meet the necessary standards for reimbursement can be a challenge.
-
Global Health Crises:
- Future pandemics or global health emergencies can disrupt operations and change demand dynamics for certain products, requiring agile business strategies.
-
Sustainability and Environmental Concerns:
- Increasing focus on sustainability can affect manufacturing processes and product designs, requiring Terumo to adapt to meet environmental standards and consumer expectations.
-
Workforce Challenges:
- Attracting and retaining skilled labor, particularly in R&D and manufacturing roles, is critical for continued innovation and operational efficiency. Labor shortages can impact production and quality.
By navigating these risks and challenges effectively, Terumo Corporation can sustain its competitive edge and continue its growth trajectory in the medical technology industry.
Revenue & Expenses Breakdown
Terumo Corp
Balance Sheet Decomposition
Terumo Corp
Current Assets | 708.8B |
Cash & Short-Term Investments | 196.7B |
Receivables | 186.6B |
Other Current Assets | 325.4B |
Non-Current Assets | 1.2T |
Long-Term Investments | 43.7B |
PP&E | 430.5B |
Intangibles | 617.1B |
Other Non-Current Assets | 69B |
Current Liabilities | 237.8B |
Accounts Payable | 86.8B |
Accrued Liabilities | 22.3B |
Other Current Liabilities | 128.7B |
Non-Current Liabilities | 212.7B |
Long-Term Debt | 159.8B |
Other Non-Current Liabilities | 52.9B |
Earnings Waterfall
Terumo Corp
Revenue
|
964.8B
JPY
|
Cost of Revenue
|
-456B
JPY
|
Gross Profit
|
508.8B
JPY
|
Operating Expenses
|
-353.7B
JPY
|
Operating Income
|
155.1B
JPY
|
Other Expenses
|
-37.4B
JPY
|
Net Income
|
117.7B
JPY
|
Free Cash Flow Analysis
Terumo Corp
JPY | |
Free Cash Flow | JPY |
In the first quarter, Terumo Corporation achieved record financial results with a 20% revenue growth, reaching JPY 258.2 billion. This was driven by strong demand in cardiovascular, neurovascular, and other segments, alongside favorable exchange rates. Operating income also reached a record high of JPY 44.6 billion due to profit improvement measures and cost control. The company projects continued strong performance, despite potential macroeconomic volatilities such as changes in raw material prices and transportation costs. Guidance remains positive, with no revisions planned for the full year.
What is Earnings Call?
Profitability Score
Profitability Due Diligence
Terumo Corp's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Terumo Corp's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Terumo Corp's solvency score is 91/100. The higher the solvency score, the more solvent the company is.
Score
Terumo Corp's solvency score is 91/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Terumo Corp
According to Wall Street analysts, the average 1-year price target for Terumo Corp is 3 374.63 JPY with a low forecast of 2 929 JPY and a high forecast of 3 885 JPY.
Dividends
Current shareholder yield for Terumo Corp is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Terumo Corp. engages in the manufacturing and sale of medical products and equipment. The company is headquartered in Shibuya-Ku, Tokyo-To and currently employs 26,482 full-time employees. The firm operates in three segments. The Cardiac and Vascular Company segment is engaged in the manufacture of catheter system and cardiopulmonary system products, the import of the cardiopulmonary systems and artificial blood vessels, as well as the sale of products mainly to hospitals and clinics nationwide through agents. The Hospital Company segment is engaged in the manufacture, purchase and sale of hospital medical equipment, pharmaceuticals, peritoneal dialysis and diabetes related products, and the rental of hospital medical equipment and home medical products. The segment is also engaged in the manufacture and sale of healthcare related products. The Blood System Company segment is engaged in the manufacture and sale of blood transfusion-related products.
Contact
IPO
Employees
Officers
The intrinsic value of one Terumo Corp stock under the Base Case scenario is 2 424.68 JPY.
Compared to the current market price of 2 921.5 JPY, Terumo Corp is Overvalued by 17%.